# Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer

> **NCT02284529** · PHASE4 · COMPLETED · sponsor: **Sinphar Pharmaceutical Co., Ltd** · enrollment: 20 (actual)

## Conditions studied

- Stage-Ⅱ Colorectal Cancer

## Interventions

- **DRUG:** Orectalip

## Key facts

- **NCT ID:** NCT02284529
- **Lead sponsor:** Sinphar Pharmaceutical Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-08
- **Final completion:** 2014-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02284529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02284529, "Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02284529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*